Literature DB >> 29185257

Optimal mesenchymal stem cell delivery routes to enhance neurogenesis for the treatment of Alzheimer's disease: optimal MSCs delivery routes for the treatment of AD.

Sang Eon Park1,2,3, Na Kyung Lee1,2,3, Duk L Na1,2,3, Jong Wook Chang2,4.   

Abstract

Alzheimer's disease (AD) is a common cause of dementia. Alzheimer's disease (AD) is characterized by progressive loss of memory in addition to cortical atrophy. Despite decades of research and therapeutic trials in AD, an effective treatment is yet to be developed. Mesenchymal stem cells (MSCs) have emerged as promising tools for the treatment of AD, and clinical trials have been completed or are in progress. MSCs secrete various cytotropic factors that may exert beneficial effects in AD. The route of administration is an important factor to enhance MSC based treatment effects for AD. Among various routes, the intracerebroventricular route may possess several advantages such as the activation of neurogenesis, compared to other routes for AD treatments. In this review, we will focus on recent pre-clinical and clinical advances in MSC-based treatment of AD, specifically in relation to enhancement of endogenous neurogenesis.

Entities:  

Mesh:

Year:  2017        PMID: 29185257     DOI: 10.14670/HH-11-950

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.303


  8 in total

1.  MicroRNA Let-7f-5p Promotes Bone Marrow Mesenchymal Stem Cells Survival by Targeting Caspase-3 in Alzheimer Disease Model.

Authors:  Linlin Han; Yan Zhou; Ruiyi Zhang; Kaimin Wu; Yanhui Lu; Yanfei Li; Ranran Duan; Yaobing Yao; Dengna Zhu; Yanjie Jia
Journal:  Front Neurosci       Date:  2018-05-22       Impact factor: 4.677

Review 2.  Mesenchymal Stem Cells for Neurological Disorders.

Authors:  Anna Andrzejewska; Sylwia Dabrowska; Barbara Lukomska; Miroslaw Janowski
Journal:  Adv Sci (Weinh)       Date:  2021-02-24       Impact factor: 16.806

3.  Intracerebroventricular injection of human umbilical cord blood mesenchymal stem cells in patients with Alzheimer's disease dementia: a phase I clinical trial.

Authors:  Hee Jin Kim; Kyung Rae Cho; Hyemin Jang; Na Kyung Lee; Young Hee Jung; Jun Pyo Kim; Jung Il Lee; Jong Wook Chang; Seongbeom Park; Sung Tae Kim; Seung Whan Moon; Sang Won Seo; Soo Jin Choi; Duk L Na
Journal:  Alzheimers Res Ther       Date:  2021-09-14       Impact factor: 6.982

Review 4.  Alzheimer's Disease: From Pathogenesis to Mesenchymal Stem Cell Therapy - Bridging the Missing Link.

Authors:  Jingqiong Hu; Xiaochuan Wang
Journal:  Front Cell Neurosci       Date:  2022-02-07       Impact factor: 5.505

Review 5.  Genetically Modified Mesenchymal Stem Cells: The Next Generation of Stem Cell-Based Therapy for TBI.

Authors:  Rami Ahmad Shahror; Chung-Che Wu; Yung-Hsiao Chiang; Kai-Yun Chen
Journal:  Int J Mol Sci       Date:  2020-06-05       Impact factor: 5.923

Review 6.  Germinal Matrix-Intraventricular Hemorrhage of the Preterm Newborn and Preclinical Models: Inflammatory Considerations.

Authors:  Isabel Atienza-Navarro; Pilar Alves-Martinez; Simon Lubian-Lopez; Monica Garcia-Alloza
Journal:  Int J Mol Sci       Date:  2020-11-06       Impact factor: 5.923

7.  Exploring the Potential of Mesenchymal Stem Cell-Based Therapy in Mouse Models of Vascular Cognitive Impairment.

Authors:  Na Kyung Lee; Hyeongseop Kim; Jong Wook Chang; Hyemin Jang; Hunnyun Kim; Jehoon Yang; Jeyun Kim; Jeong Pyo Son; Duk L Na
Journal:  Int J Mol Sci       Date:  2020-08-01       Impact factor: 5.923

8.  ADMSC Exo-MicroRNA-22 improve neurological function and neuroinflammation in mice with Alzheimer's disease.

Authors:  Liping Zhai; Heping Shen; Yongjia Sheng; Qiaobing Guan
Journal:  J Cell Mol Med       Date:  2021-07-11       Impact factor: 5.310

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.